Release Notes: Version 20181113
General Notes
The following files will be available as full release files within this version:
- Manufactured Product,
- Non-proprietary Therapeutic Product,
- Therapeutic Moiety,
- Manufactured Product, Non-proprietary Therapeutic Product, Therapeutic Product Relationship,
- Special Groupings,
- Coded Attribute, and
- Device Non-proprietary Therapeutic Product.
The 'Full" release contains one entry for every concept that has ever been released and new content added for that release. New content added for a specific release may at times include “Inactive” content.
NOTE: The “Delta" release which is intended to contain only those concepts that have been added or changed since the previous release will be considered for a future enhancement at a later date.
This release continues to add additional content from the DPD and includes most of the top 250 moieties and approximately 86% of the DPD content in scope for CCDD.
The table below provides the number of concepts within each CCDD file for this release.
November 2018 CCDD Files | Number of Concepts | Types of Changes in this release |
|---|---|---|
| Therapeutic Moiety Full Release | 1108 | 112 additions 1 status change from active to inactive 1 status change from active to deprecated (see details below) |
| Non-proprietary Therapeutic Product Full Release | 3268 | 247 additions (242 for new TMs; 4 new-correction and 1 totally new NTP for existing TMs) 3 NTP formal name changes (see details below) 4 status changes from active to inactive 12 status date changes (with no change of status) 3 status change from active to deprecated (see details below) 11 existing deprecated concepts changed status date |
| Manufactured Product Full Release | 9576 | 434 additions (see specific details below)
Formal name changes made:
19 status changes from active to inactive 6 status changes from inactive to active 17 status date changes (no change of status) 2 status changes from active to deprecated (see details below) |
Manufactured Product, Non-proprietary Therapeutic Product, Therapeutic Moiety Relationship | 9573 | Includes concept additions and changes as above Deprecated concepts have been excluded. Note also that the two entries relating to the deprecated ensulizole products have been removed |
| Device Non-proprietary Therapeutic Product | 3 | no change |
| Special Groupings | 1550 | 23 additional entries due to new concepts 35 changes due to product and product+company name changes 2 changes due to products changing policy type code (dextroamphetamine - see below) 3 sets of data removed (dextroamphetamine - see below) |
| Coded Attributes | 7 | no change |
TM Changes
The following TM concept was added to the October Release in error. As a sunscreen and cosmetic product, this concept is out of the current scope of the CCDD. It has been deprecated in the November Release.
Code | Formal Name |
8001643 | ensulizole |
NTP Changes
The following NTP concept was added to the October Release in error. As a sunscreen and cosmetic product, this concept is out of the current scope of the CCDD. It has been deprecated in the November Release.
NTP Code | NTP Formal Name |
9005130 | ensulizole 3 % cutaneous emulsion |
The following NTP errors previously published have been addressed in the November Release. The product strength has been corrected resulting in the creation of 2 new NTP concepts; two existing concepts have been deprecated.
November Release | October Release | ||||
NTP Code | NTP Formal Name | Status | NTP Code | NTP Formal Name | Status |
9013290 | ethinyl estradiol 35 mcg per 24 hours and norelgestromin 200 mcg per 24 hours transdermal patch | Active | |||
9013289 | ethinyl estradiol 30 mcg and levonorgestrel 150 mcg oral tablet with ethinyl estradiol 10 mcg oral tablet | Active | |||
9006562 | ethinyl estradiol 35 mcg per 24 hours and norelgestromin 20 mcg per 24 hours transdermal patch | Deprec | 9006562 | ethinyl estradiol 35 mcg per 24 hours and norelgestromin 20 mcg per 24 hours transdermal patch | Active |
9009384 | ethinyl estradiol 30 mcg and levonorgestrel 150 mcg oral tablet with ethinyl estradiol 100 mcg oral tablet | Deprec | 9009384 | ethinyl estradiol 30 mcg and levonorgestrel 150 mcg oral tablet with ethinyl estradiol 100 mcg oral tablet | Active |
The following two new NTPs have been created for SENSORCAINE products (see below). The NTPs previously associated with the SENSORCAINE products continue to be used by other MPs and therefore do not need deprecating.
NTP Code | NTP Formal Name |
9013269 | bupivacaine hydrochloride 25 mg per 10 mL solution for injection ampoule |
9013270 | bupivacaine hydrochloride 50 mg per 10 mL solution for injection ampoule |
The following three NTPs have had a name change due to changes made within the DPD. The changes have not altered the meaning of the concepts therefore the NTP code is unchanged.
November Data | October Data | Reason | ||
NTP Code | NTP Formal Name | NTP Code | NTP Formal Name | |
9001070 | montelukast (montelukast sodium) 4 mg per sachet granules for oral suspension | 9001070 | montelukast (montelukast sodium) 4 mg per pck granules for oral suspension | DPD strength now “per sachet” |
9004200 | dextromethorphan hydrobromide 5 mg and phenylephrine hydrochloride 2.5 mg orodispersible film | 9004200 | dextromethorphan hydrobromide 5 mg and phenylephrine hydrochloride 2.5 mg orodispersible tablet | DPD update to dose form |
9001231 | esomeprazole (esomeprazole magnesium) 10 mg per sachet gastro-resistant granules for oral suspension | 9001231 | esomeprazole (esomeprazole magnesium) 10 mg per pck gastro-resistant granules for oral suspension | DPD strength now “per sachet” |
MP Changes
The following MP concepts were added to the October Release in error. As sunscreen and cosmetic products, these concepts are out of the current scope of the CCDD. They have been deprecated in the November Release.
MP Code | MP Formal Name |
02381788 | COVERGIRL OUTLAST ALL DAY STAY FABULOUS 3-IN-1 FOUNDATION (ensulizole 3 % cutaneous emulsion) HFC PRESTIGE INTERNATIONAL CANADA INC |
02459027 | COVERGIRL VITALIST ELIXIR FOUNDATION (ensulizole 3 % cutaneous emulsion) HFC PRESTIGE INTERNATIONAL CANADA INC |
The following MP concepts are now associated with new NTPs to correct a unit of presentation error:
November Release | October Release | ||
MP Code | MP Formal Name | MP Code | MP Formal Name |
77700656 | SENSORCAINE (bupivacaine hydrochloride 25 mg per 10 mL solution for injection ampoule) ASPEN PHARMACARE CANADA INC. | 77700656 | SENSORCAINE (bupivacaine hydrochloride 25 mg per 10 mL solution for injection vial) ASPEN PHARMACARE CANADA INC. |
77700658 | SENSORCAINE (bupivacaine hydrochloride 50 mg per 10 mL solution for injection ampoule) ASPEN PHARMACARE CANADA INC. | 77700658 | SENSORCAINE (bupivacaine hydrochloride 50 mg per 10 mL solution for injection vial) ASPEN PHARMACARE CANADA INC. |
The following MP concept errors previously published have been addressed in the November Release. The MP code remains the same, but the strength has been corrected.
November Release | October Release | ||
MP Code | MP Formal Name | MP Code | MP Formal Name |
02248297 | EVRA (ethinyl estradiol 35 mcg per 24 hours and norelgestromin 200 mcg per 24 hours transdermal patch) JANSSEN INC | 02248297 | EVRA -(6/0.60) (ethinyl estradiol 35 mcg per 24 hours and norelgestromin 20 mcg per 24 hours transdermal patch) JANSSEN INC |
02346176 | SEASONIQUE (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg oral tablet with ethinyl estradiol 10 mcg oral tablet) TEVA WOMEN'S HEALTH INC | 02346176 | SEASONIQUE (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg oral tablet with ethinyl estradiol 100 mcg oral tablet) TEVA WOMEN'S HEALTH INC |
Special Grouping File Changes
Three sets of data previously present in the Special Groupings File have been removed due to updates to the DPD drug schedule information for dextroamphetamine. These are:
ccdd_code | ccdd_formal_name | ccdd_type | policy_type | policy_reference | special_groupings_status | special_groupings_status_effective_time |
8000162 | dextroamphetamine | TM | 500002 | http://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html | Active | 20170919 |
9000414 | dextroamphetamine sulfate 10 mg prolonged-release oral capsule | NTP | 500002 | http://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html | Active | 20170919 |
9000415 | dextroamphetamine sulfate 15 mg prolonged-release oral capsule | NTP | 500002 | http://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html | Active | 20170919 |
In addition, two sets of data have been changed to be in line with the DPD drug schedule information for dextroamphetamine. These are:
| November Release | October Release | |||
ccdd_code | ccdd_formal_name | policy_type | policy_reference | policy_type | policy_reference |
02448319 | ACT DEXTROAMPHETAMINE SR (dextroamphetamine sulfate 10 mg prolonged-release oral capsule) ACTAVIS PHARMA COMPANY | 500003 | http://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html | 500002 | http://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html |
02448327 | ACT DEXTROAMPHETAMINE SR (dextroamphetamine sulfate 15 mg prolonged-release oral capsule) ACTAVIS PHARMA COMPANY | 500003 | http://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html | 500002 | http://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html |
Questions, Concerns, Changes
Questions and concerns and suggestions for future consideration are welcomed and should be sent by e-mail at [email protected]
Please note that to access InfoCentral, you must have an Infoway login. If you have any questions about any of our standards or products, please contact the Infodesk Desk at:
Toll Free #: 1-877-595-3417 or 416-595-3417
E-mail: [email protected]